Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Phase IB/II trial of epcoritamab plus ibrutinib in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

RWRina Li WelkieTVTimothy VoorheesLALapo Alinari

Discussion

Loading...

Member takes

Overview

Phase Ib/II trial shows promising complete response in large B-cell lymphoma, suggesting improved outcomes with ibrutinib and epcoritamab.

Key Points

  • To determine the recommended phase II dose of epcoritamab and ibrutinib and evaluate cytokine release syndrome.
  • Multicenter Phase Ib/II trial in patients with relapsed large B-cell lymphoma
  • Combination of epcoritamab and ibrutinib with a lead-in period
  • Safety evaluation and overall response rate assessment
  • High complete response rates observed in treatment arms
  • Reduced severity of cytokine release syndrome noted
  • Progression-free survival outcomes will be characterized post-trial

Cite This Study

Welkie et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e32chttps://doi.org/10.1182/blood-2025-8239
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase ib study to assess the efficacy and safety of epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorder2025
  2. 2Trial in progress: Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma2025 · 1 citations
  3. 3Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab2026
  4. 4Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial2026 · 4 citations
  5. 5Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial2026